Nebenwirkungen · Ristfor
Ristfor 50 mg/850 mg film-coated tablets Ristfor 50 mg/1 000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 10
HOS-213159 · Präparat HOS-155044
In the intention-to-treat population, among patients who were using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycaemia was 2.7 % in sitagliptin-treated patients and 2.5 % in placebo-treated patients; among patients who were not using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycaemia was 1.0 % in sitagliptin-treated patients and 0.7 % in placebo-treated patients. The incidence of adjudication-confirmed pancreatitis events was 0.3 % in sitagliptin-treated patients and 0.2 % in placebo-treated patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T16:59:00Z · SHA-256 b5a5e03c53fc129476a3d12e1af9319ad9c05981058770a65f90dce0b54d48da · Passage 5a30eb64f37583e8f149fa29903b78b2b41654002b79ba9a30b0f66a494ddf29 · Zeichen 7043–7609 im Abschnitt